Chiadi E. Ndumele, M.D., Ph.D., M.H.S., FAHA, stood at the threshold of a medical breakthrough when the American Heart Association and American College of Cardiology—joined by two other leading medical organizations—released the first-ever clinical guideline for cardiovascular-kidney-metabolic syndrome. The moment matters because it represents a fundamental shift in how doctors think about three conditions that have long been treated in isolation: heart disease, kidney disease, and metabolic dysfunction.
Nearly 90% of American adults carry at least one risk factor for CKM syndrome—excess weight, high blood pressure, abnormal cholesterol, elevated blood sugar, or reduced kidney function. This isn't a rare condition affecting a sliver of the population. It's a pervasive health crisis that demands a new framework for understanding and prevention. "Heart, kidney, and metabolic conditions don't occur in isolation—they are deeply connected," said Ndumele, director of obesity and cardiometabolic research at Johns Hopkins School of Medicine in Baltimore and chair of the writing committee. "This guideline calls for earlier screening and care, focusing on prevention and coordinated action to reduce the risk of cardiovascular disease before serious complications develop or a major cardiac event occurs."
The guideline, published in both Circulation and JACC, introduces four distinct stages of CKM syndrome that allow clinicians and individuals to identify risk earlier and tailor prevention strategies accordingly. Stage 1 captures those with overweight, obesity, or prediabetes without other complications. Stage 2 includes those with metabolic risk factors like high blood pressure or Type 2 diabetes, or kidney disease, but no cardiovascular disease. Stage 3 identifies people with subclinical cardiovascular disease or very-high-risk kidney disease. Stage 4 encompasses those already diagnosed with heart disease, stroke, or other serious cardiovascular conditions alongside metabolic or kidney concerns. This staging system transforms abstract risk into actionable categories.
The recommendations themselves are grounded in practical tools and strategies. Clinicians now have access to the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations, which estimate 10- and 30-year cardiovascular risk while incorporating kidney and metabolic health factors—a more precise approach than previous assessment tools. The guideline also emphasizes screening for social factors: food insecurity, housing instability, and financial strain all increase the likelihood of developing CKM syndrome, yet are rarely assessed in routine care.
Treatment options have expanded significantly. Beyond the traditional focus on physical activity, nutrition, blood pressure management, and cholesterol control, the guideline now includes recommendations for GLP-1-based therapies for select individuals with obesity and Type 2 diabetes who face elevated cardiovascular risk. Metabolic and bariatric surgery are also recognized as treatment options. This represents the first time GLP-1 therapies have been formally recommended at this clinical level for cardiovascular protection.
The statistics underscore the urgency. Forty percent of U.S. adults and 21% of children and adolescents live with obesity, which opens the door to high blood pressure, diabetes, cardiovascular disease, and kidney disease. Yet this new guideline offers something rarer than statistics: a coordinated, evidence-based roadmap that asks doctors and patients to act earlier, to screen more comprehensively, and to address the interconnected nature of these conditions together rather than piecemeal. For the millions of Americans carrying CKM risk factors, that shift from reaction to prevention could reshape their health trajectories.